Download presentation
Presentation is loading. Please wait.
Published byΠρίσκιλλα Κοσμόπουλος Modified over 6 years ago
1
Real-World Evidence: What Is It and Why Is It so Important In MS?
3
This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.
4
Introduction
6
Information Gained From RCTs and Observational Data
7
Information Gained From RCTs and Observational Data: Limitations
8
Sources of RWE: Advantages and Limitations
9
Checklist for High Quality RWE Studies
10
Summary of Key Points
11
Sources of RWE: Structured Databases
12
MSBase Registry
13
MSBase: Learnings About Effect of Early Treatment on Conversion to SPMS
14
Potential for Learning About Treatment Optimization
15
MS Registries and Cohorts: A Sample
16
Treatment-Related Data Collection in Germany: PANGAEA Observational Study
17
Need for Widespread Data Collection: Complementary to RCTs
18
Advantages and Challenges of RCTs and RWE
19
Propensity Score
20
Propensity Score Matching
21
Propensity Score Matching: Controlling for Variables
22
Propensity Score-Based Methods in Cardiology
23
Propensity Score-Based Method: Coffee and Mortality
24
Distribution of Propensity Scores Before and After Matching
25
MSBase Propensity-Matched Data: Escalation to Natalizumab vs Fingolimod in Active RRMS
26
Propensity-Matched Comparison of Sick Days: PEARL and PANGAEA Observational Studies
27
Bias in Observational Studies: Checklist
28
Smoking and MS Progression: Swedish National MS Registry
29
Swedish Registry Disability Outcomes: Developing an Age-Related MS Severity Score
30
Vast Amounts of Data Are Needed
31
Individualized Treatment and Big-Data RWE: A Combined Approach
32
Impactful RWE Requires Structured Data Collection
33
Concluding Remarks
34
Abbreviations
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.